Invesco Variable Rate Investment Grade ETF (NASDAQ: VRIG)

Latest news for Invesco Variable Rate Investment Grade ETF (NASDAQ:VRIG)

Invesco Variable Rate Investment Grade ETF

The fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in a portfolio of investment-grade, variable rate or floating rate debt securities. At least 80% of its net assets (plus any borrowings for investment purposes) will be invested in Variable Rate Instruments that are, at the time of purchase, investment grade (or in affiliated ETFs that invest primarily in any or all of the foregoing securities).

COSCIENS Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCI#NASDAQ">CSCI</a>) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CSCI#TSX">CSCI</a>) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today provided a corporate update and reiterated its pipeline prioritization.
"Over the course of the last several months following the merger, we have taken strategic and deliberate steps to evaluate and prioritize our combined pipeline of products and programs. Through this effort, we have thoroughly evaluated the potential of our assets and prioritized the areas that we believe are high-value opportunities, and we plan to move forward focusing our resources on advancing a pipeline of natural-based products leveraging our core technologies. We believe that this focus, spanning cosmeceuticals, nutraceuticals and pharmaceuticals, positions us with near and long-term life science growth drivers and the potential to become a global leader in natural-based products for health and wellness," stated <a href="https://www.globenewswire.com/Tracker?data=XGEB5e3QJGs0rAZIEn9x3enzUNiQFyPKt0kKPnr1xjTKfNlMsAdacP2YgVUlHhRD5gSQwGVhUPozg71YRlEgMHW38CEK1DDrHxEAYh0ecfkZ-ZDfyBuCxSyjQEpSMY-zoQ4WmYnYksKrGXJWHDk_2w==">Gilles Gagnon, M.Sc., MBA, President and CEO</a> of COSCIENS. "In addition, we have continued to make progress driving revenues and growing our active ingredients base business. We are looking to kick off 2025 with a clear line of sight towards execution of our business plan and believe we are well-positioned for a transformational year."
Development Projects Update
Pharmaceuticals:
<ul>
<li>Avenanthramides Tablets (Avs) in Development as an Anti-Inflammatory: The Phase 1-2a clinical trial being conducted at the Montreal Heart Institute has fully completed the Phase 1 part of the study with 72 subjects tested. No significant side effects have been observed from ascending doses ranging from 30 mg to 960 mg. The Company expects the Phase 2a efficacy study will be initiated in Q1 2025, with expected completion in Q3 2025. &nbsp;</li>
</ul>
Cosmeceuticals:
<ul>
<li>Enriched Oat Flour with High Concentration of Avenanthramides: We have successfully produced and sold small batches for inclusion in cream formulations. &nbsp;</li>
<li>JuventeDC Product Line: New website, <a href="https://juventedc.com/en">juventedc.com</a>, was launched on December 19, 2024. &nbsp;</li>
</ul>
Nutraceuticals:
<ul>
<li>Yeast Beta Glucan (YBG) Powder - Immune Booster: Our YBG product has been successfully manufactured as part of our PGX scale up project in Edmonton, Alberta. Our YBG product is being finalized in capsule form with the goal to commercialize it as an immune booster in Q2 2025. &nbsp;</li>
<li>Oat Beta Glucan (OBG) Chewable Bar – Cholesterol Reduction: We have successfully developed a unique, standardized formulation for a healthy confection which includes a high concentration of OBG with daily dosage according to approved claims in 10 developed countries. The substantive claims include reduction of LDL cholesterol, supporting cardiovascular health reduction of Type 2 diabetes risks, source of fiber for the maintenance of general good health and support of a healthy digestive system. COSCIENS' team anticipates the official commercial launch of its chewable bar OBG natural health product in Q1 2025, marking an important chapter in the Company's journey toward promoting wellness while expanding its business model. &nbsp;</li>
</ul>
Macimorelin:
<ul>
<li>On August 27, 2024, the Company announced that the Phase 3 safety and efficacy study AEZS-130-P02 (the "DETECT-trial") evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency ("CGHD") had failed to meet its primary endpoints according to the definitions in the study protocol. Based on the results of the study, we are prioritizing our pipeline moving forward and repositioning the Company as a pure play Life Science's business offering natural-based products. Therefore, while maintaining the current commercial indication for the use of macimorelin for the diagnosis of Adult Growth Hormone Deficiency ("AGHD"), the Company has decided to not make any future investments in macimorelin for the diagnosis of CGHD. Consequently, in order to further ensure the streamlining of operations and reduce costs, the roles of some additional members of management have been terminated, including Dr. Nicola Ammer, Chief Medical Officer, which will be ending on March 31, 2025. &nbsp;</li>
</ul>

News

CSCI

TSX:CSCI

COSCIENS Biopharma Shifts Focus to Natural-Based Products for Health & Wellness

Barclays analyst David Strauss maintains Textron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) with a Overweight and lowers the price target from $104 to $95.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Textron, Lowers Price Target to $95

Ennis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBF#NYSE">EBF</a>) just disclosed its Q3 earnings on Monday, December 23, 2024 at 06:00 AM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Ennis missed estimated earnings by 0.0%, reporting an EPS of $0.39 versus an estimate of $0.39.
Revenue was down $4.85 million from the same period last year.
<h3>Historical Earnings Summary</h3>
The company missed on EPS by $0.02 in the last quarter, resulting in a 2.0% increase share price change the following day.
Here's a look at Ennis's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.42</td>
<td>0.36</td>
<td>0.39</td>
<td>0.42</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.40</td>
<td>0.41</td>
<td>0.39</td>
<td>0.38</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>104.58M</td>
<td>100.85M</td>
<td>101.40M</td>
<td>102.40M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>99.04M</td>
<td>103.11M</td>
<td>97.43M</td>
<td>104.62M</td>
</tr>
</tbody>
</table>

 Listen to the earnings announcement yourself by <a href="">clicking here</a>. 
To track all earnings releases for Ennis <a href="https://www.benzinga.com/quote/EBF/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Ennis: Q3 Earnings Insights

Stifel analyst Benjamin Nolan maintains New Fortress Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) with a Buy and raises the price target from $16 to $17.

Stifel Maintains Buy on New Fortress Energy, Raises Price Target to $17

Chinese company Sophgo whose Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)-made chip was allegedly found in a Huawei Technologies Co artificial-intelligence processor, faces potential blacklisting from the U.S.
Bitcoin mining equipment supplier Bitmain affiliate Sophgo is the latest Chinese company potentially on the U.S. semiconductor embargo list, citing national security threats, Reuters reports.
In October, tech research firm TechInsights reportedly discovered the Taiwan Semiconductor chip in the Huawei 910B and told the chipmaker, which notified the U.S. Commerce Department.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/12/42621868/nvidia-secures-eu-approval-for-runai-deal-us-probes-china-export-breach" rel="noreferrer noopener">Nvidia Secures EU Approval For Run:ai Deal, US Probes China Export Breach</a>
After determining the chip matched Sophgo&#8217;s design, Taiwan Semiconductor suspended <a target="_blank" href="https://www.benzinga.com/government/24/10/41573440/whats-going-on-with-taiwan-semiconductor-stock-on-monday" rel="noreferrer noopener">shipments to the company</a>.
Sophgo, a supplier to local governments and state-owned firms like China Telecom, denied the charges in October. Huawei also denied the allegations, Reuters report said.
On November 11, the U.S. urged Taiwan Semiconductor to suspend shipments of seven-nanometer or more advanced chips to China. The U.S. sanctions forbid exporters from shipping goods and technology without a license, which will likely be denied.
In December, the <a target="_blank" href="https://www.benzinga.com/government/regulations/24/12/42265847/biden-targets-china-with-new-chip-restrictions-nvidia-slides." rel="noreferrer noopener">U.S. government sanctioned</a> 140 Chinese semiconductor firms, including chip equipment manufacturers such as&nbsp;Naura Technology Group and others, targeting advanced memory chips and chipmaking tools.
The U.S. added telecom equipment maker Huawei to its Entity List in 2019, restricting its access to foreign-made chips since 2020. However, over the past two years, Chinese state-run universities building AI tools and police stations splurged on Sophgo and Bitmain AI chips to upgrade their capabilities.
The U.S. sanctions prompted Huawei to diversify into an AI chip powerhouse. China considers Huawei&#8217;s Ascend 910B the most advanced AI chip in the country. Huawei plans to commercialize its Ascend 910C in early 2025 to rival Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Taiwan Semiconductor stock is trading upwards on Monday. At the end of last week, the Taiwanese contract chipmaker&#8217;s stocks were trading at ~ a 25% premium to those in its domestic market, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-12-23/us-investors-pay-biggest-premium-for-tsmc-shares-in-two-months?srnd=phx-technology&amp;sref=TBDibEcD" rel="noreferrer noopener">reports</a>, signaling investors&#8217; conviction in the AI frenzy.
This marks a record premium since October 17, beating the quarter&#8217;s daily average of 19%.
Price Action: TSM stock is up 1.75% at $200.67 premarket at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42614272/us-listed-chinese-stocks-react-as-central-bank-keeps-key-rates-steady-amid-yuan-challenges-and-fed-cuts" target="_blank" rel="noreferrer noopener">US-Listed Chinese Stocks Fall As China&#8217;s Central Bank Keeps Key Rates Steady</a></li>
</ul>
Photo via Shutterstock

Government

Regulations

Emerging Markets

Tech

Media

NVDA

Biden Administration Targets Chinese Firm Over Taiwan Semiconductor Chip Found in Huawei Tech

Barclays analyst Balaji Prasad maintains Revance Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) with a Equal-Weight and lowers the price target from $7 to $3.

RVNC

Barclays Maintains Equal-Weight on Revance Therapeutics, Lowers Price Target to $3

Stifel analyst Stephen Gengaro maintains Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) with a Buy and lowers the price target from $60 to $59.

Stifel Maintains Buy on Schlumberger, Lowers Price Target to $59

Barclays analyst Ramsey El-Assal maintains Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) with a Equal-Weight and raises the price target from $135 to $140.

PAYX

Barclays Maintains Equal-Weight on Paychex, Raises Price Target to $140

Shares of Rumble Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) rose sharply in today's pre-market trading after the company announced it has entered into a definitive agreement for a strategic <a href="https://www.benzinga.com/24/12/42634166/rumble-stock-soars-on-775-million-investment-from-tether-what-to-know">investment of $775 million from Tether</a>.
Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>) has agreed to purchase 103.33 million shares of Rumble Class A Common Stock at a price per share of $7.50, totaling $775 million in gross proceeds to Rumble.
Rumble shares jumped 43.3% to $10.31 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Reliance Global Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) gained 234% to $4.01 in pre-market trading.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) gained 88.6% to $3.32 in pre-market trading. Phio Pharmaceuticals, last week, announced a $1.15 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Edible Garden AG Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) climbed 82.3% to $0.4334 in pre-market trading after surging 63% on Friday. Edible Garden recently announced it experienced a 51% year-over-year increase in its preliminary Thanksgiving period sales.</li>
<li>JIADE Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) gained 60.9% to $0.8530 in pre-market trading. JIADE received Nasdaq notification letter regarding minimum bid price deficiency.</li>
<li>American Battery Technology Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABAT#NASDAQ">ABAT</a>) rose 44.1% to $1.60 in pre-market trading. On Friday, American Battery Technology priced its $5 million registered direct offering of 5 million shares at $1.00 per share.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) gained 30.9% to $3.60 in pre-market trading after jumping more than 36% on Friday.</li>
<li>Brenmiller Energy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>) rose 28.8% to $0.9700 in pre-market trading after the company was awarded ISO/IEC 27001:2022 certification.</li>
<li>Honda Motor Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) gained 18% to $28.19 in pre-market trading. Honda Motor and Nissan Motor Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSANY#OTC">NSANY</a>) have started talks for a potential merger.</li>
<li>Kodiak Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) rose 14.9% to $9.94 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares tumbled 28.9% to $0.0531 in pre-market trading after jumping 14% on Friday. Conduit Pharmaceuticals recently announced it entered an agreement with Sarborg to leverage AI and its cybernetics platform to evaluate key deliverables across multiple areas of operations.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) declined 25.7% to $0.6759 in pre-market trading after jumping around 101% on Friday.</li>
<li>Onfolio Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONFO#NASDAQ">ONFO</a>) fell 24.4% to $1.21 in pre-market trading. Onfolio Holdings announced a quarterly preferred stock cash dividend of 75 cents per share.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) shares fell 24.3% to $0.6703 in pre-market trading after declining 9% on Friday.</li>
<li>ConnectM Technology Solutions Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) shares dipped 20% to $0.83 in pre-market trading after falling 8% on Friday. ConnectM Technology Solutions, last week, announced a year-over-year increase in third-quarter revenue results.</li>
<li>TPI Composites, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) fell 19.2% to $1.94 in today's pre-market trading after jumping 97% on Friday.</li>
<li>Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) dipped 17.8% to $0.2293 in pre-market trading after jumping 64% on Friday. Aptose Biosciences, last week, announced it was granted an extension to provide compliance evidence for a continued Nasdaq listing.</li>
<li>Core Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLB#NYSE">CLB</a>) fell 11% to $15.00 in pre-market trading.</li>
<li>Astria Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) shares fell 10.8% to $8.53 in pre-market trading.</li>
<li>SIGA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) fell 8.5% to $5.41 in pre-market trading.</li>
</ul>
Now Read This: &lt;a href=&#8221;https://www.benzinga.com/news/earnings/24/04/38307448/investor-sentiment-decreases-further-s-p-500-falls-for-fourth-straight-session&#8221;&gt;&lt;em&gt; Investor Sentiment Decreases Further, S&amp;P 500 Falls For Fourth Straight Session&lt;/em&gt;&lt;/a&gt;

Pre-Market Outlook

Markets

Movers

Trading Ideas

$USDT

ABAT

AILE

APTO

ATXS

BNRG

CNTM

EDBL

HSDT

JDZG

LAES

NSANY

ONFO

PHIO

RELI

SIGA

TPIC

Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

Stifel analyst Steven Wieczynski maintains Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) with a Buy and raises the price target from $32 to $34.

Stifel Maintains Buy on Carnival, Raises Price Target to $34

CleanSpark Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>), America's Bitcoin Miner&#xAE; (the "Company"), today announced it has achieved and exceeded the previously announced year-end target of 37 EH/s of operating hashrate.
&nbsp;
The Company's newest data centers in Tennessee and Wyoming were energized last week. This is part of a multistage energization process that will continue into the next quarter. The added hashrate from these sites paired with site expansion, and ongoing fleet upgrades, has allowed the Company to exceed 2024 YE guidance and deliver 37.5 EH/s of operating hashrate. Fleet efficiency has reached 17.7 J/Th and is expected to continue to improve as the Company continues its strategic growth plans. The Company expects its operating leverage to continue to increase as it proceeds with its next phase of growth to 50 EH/s, which is fully funded and expected in the first half of 2025. This growth is expected to be achieved through a mix of greenfield infrastructure development, organic growth via existing site expansion, and strategic M&amp;A, all funded with a portion of the proceeds of the Company's most recent offering. The current portfolio of data centers includes locations in Georgia, Wyoming, Tennessee, Mississippi, and New York. &nbsp;&nbsp;

CLSK

CleanSpark Expands Data Centers, Surpasses 2024 Bitcoin Mining Target with 37.5 EH/s Hashrate, Aims for 50 EH/s in Early 2025

Truist Securities analyst Srikripa Devarakonda maintains Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) with a Buy and lowers the price target from $100 to $43.

KROS

Truist Securities Maintains Buy on Keros Therapeutics, Lowers Price Target to $43

The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia
Phase 1b clinical trial will assess safety and tolerability along with biomarkers during three months of dosing with GT-02287 in people diagnosed with Parkinson's disease
Phase 1b clinical trial follows successful Phase 1 study in which GT-02287 was safe and well tolerated while demonstrating GCase target engagement

GANX

Gain Therapeutics Initiated Phase 1b Clinical Trial Of Lead Candidate GT-02287 In People With GBA1 And Idiopathic Parkinson's Disease

Barclays analyst Carter Gould maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Overweight and raises the price target from $160 to $165.

NBIX

Barclays Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $165

NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) ("NewGen" or the "Company") today announced that both parties involved in the previously announced reverse merger with European Wellness Investment Holdings Limited ("EWIHL") have appointed legal counsel to prepare the Share Purchase Agreement (the "SPA"). Additionally, by mutual consent, the signing date for the SPA has been extended from January 27, 2025, to February 28, 2025. This extension will allow both parties sufficient time to complete the necessary due diligence, finalize the terms of the agreement, and ensure compliance with all relevant NASDAQ requirements for reverse mergers.
This significant step follows the Company's&nbsp;prior announcement of a binding term sheet on December 11, 2024, which marked a pivotal moment in the Company's strategic partnership with EWIHL. This collaboration aims to leverage synergies between both companies to enhance service delivery and expand market reach in the healthcare sector.

NIVF

NewGenIvf Extends Reverse Merger Deadline to Finalize Agreement with EWIHL

Raymond James analyst Buck Horne upgrades Weyerhaeuser (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) from Market Perform to Outperform and announces $32 price target.

Upgrades

Raymond James Upgrades Weyerhaeuser to Outperform, Announces $32 Price Target

QuickLogic Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUIK#NASDAQ">QUIK</a>), a developer of embedded FPGA (eFPGA) Hard IP, ruggedized FPGAs, and endpoint AI solutions, announced today it has been awarded a $6.575 million contract. This funding will support the continued development and demonstration of Strategic Radiation Hardened (SRH) high reliability Field Programmable Gate Array (FPGA) technology. The initiative aims to meet current and future Department of Defense (DoD) strategic and space system requirements.

QUIK

QuickLogic Secures $6.6M Contract to Advance Radiation-Hardened FPGA Tech for DoD

RUM: 53% &#x7C; <a href="https://www.benzinga.com//node/42631159">Rumble shares are trading higher after the company announced it has entered into a definitive agreement for a strategic investment of $775 million from Tether.</a>
&nbsp;
TRAW: 212% &#x7C; <a href="https://www.benzinga.com//node/42643986">Traws Pharma Advances One-Dose Bird Flu Treatment with Results</a>
&nbsp;
RAPT: 94% &#x7C; <a href="https://www.benzinga.com//node/42644215">RAPT Therapeutics To Raise $150M in Private Placement to Advance Drug Pipeline</a>

RAPT

TRAW

Market-Moving News for December 23rd

Raymond James analyst Buck Horne upgrades PotlatchDeltic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NASDAQ">PCH</a>) from Market Perform to Outperform and announces $45 price target.

Raymond James Upgrades PotlatchDeltic to Outperform, Announces $45 Price Target

Alliance Global Partners analyst Aaron Grey initiates coverage on Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) with a Buy rating and announces Price Target of $2.

Comments

Invesco Variable Rate Investment Grade ETF

News

Latest news for Invesco Variable Rate Investment Grade ETF (NASDAQ:VRIG)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga